Company Profile

Innovation is in the target, Value is in the team

ElsaLys Biotech is a clinical stage immuno-oncology company that designs and develops a new generation of therapeutic antibodies that target tumors and their immune and/or vascular microenvironment. By modulating the action of immune cells (immunomodulator antibodies) or by blocking the mechanisms that promote tumor growth (targeted antibodies), ELSALYS BIOTECH intends to offer new options to patients for whom therapy is no longer an option.

To convert these novel targets into drug candidates, the Company relies on a world-class academic network, a team and an R&D platform that encompasses targets sourcing to clinical development and the commercialization of monoclonal antibodies derived from these targets. Today ElsaLys Biotech is conducting 5 proprietary development programs including LEUKOTAC® (inolimomab), an immunotherapy antibody that has recently demonstrated its clinical superiority in Phase 3 in an orphan disease with very poor prognosis: steroid-resistant acute Graft-versus-Host Disease. Bringing LEUKOTAC® to the market could lead ELSALYS BIOTECH to build, by acquisitions, a portfolio of commercial immunotherapy antibodies against rare diseases.

Founded in 2013, ElsaLys Biotech is located in the heart of the European cluster Lyon Biopole. Its founding shareholders are Transgene and Sofimac Partners, joined in 2015 by the IM Europe and Crédit Agricole Création.


SHAREHOLDERS and PARTNERS

Funding history:

  • April 2013: incorporation
  • May 2013: € 2.2m from Transgene and Sofimac Partners
  • July 2013- January 2014: € 0.7m grants from BPI France and Alsace Region
  • November 2015 : 2.7 million of a total fundraising amounting to € 5 million subscribed by Sofimac Partners, IM Europe and Crédit Agricole Création

 

Shareholders:

  • Sofimac Partners
  • Transgene
  • IM Europe
  • Crédit Agricole Création
  • Business Angel

 

Institutional Support:

  • Bpifrance
  • Alsace Region

Skills and assets

A team of experts covering from target sourcing to clinical development of drug candidates

The skills of the Company range from target sourcing to clinical development of drug candidates. To this end, the ElsaLys Biotech team combines:

  • Solid knowledge in immunology and cancer and a strong academic, clinical and industrial network to identify as early as possible high potential targets identified by researchers.
  • Perfect mastery of recombinant antibody technology (whole antibodies, fragments, chimeric or humanized antibodies).
  • Expertise (cellular, molecular immunology and immuno-pharmacology) and tools (in vitro and in vivo models and biological samples from patients) to confirm, as closely as possible to reality, the real efficacy and safety of candidate antibodies.
  • Clinical experience to select the most relevant indication, identify and validate potential therapeutic combinations and secure the future clinical development plan of the drug candidate.
  • Unique know-how in bio-manufacturing, which today enables ElsaLys Biotech to produce pre-industrial antibody candidates through a wide range of expression systems.
  • A project management industry standard (for each program, a scientific coordinator monitors the Gantt chart and advancement of the deliverables borne internally or through academic laboratory partners or service companies).  

In addition, ElsaLys Biotech relies on a network of actors and opinion leaders in the specific field of antibodies (research, clinical, regulatory, patent, CMC, toxicology).


Network


Financial Partners


Academic and industrial partners


R&D Pipeline

NEW GENERATION OF THERAPEUTIC ANTIBODIES THAT TARGET TUMORS AND THEIR IMMUNE AND/OR VASCULAR MICROENVIRONMENT

In less than 4 years, ElsaLys Biotech has already signed licensing option and/or collaboration agreements (Institut Curie, IGBMC-ICS, Centre Léon Bérard, Skin Research Center, PDCC) and maturation agreements, and has acquired 3 strategic assets from MABLIFE, TRANSGENE and JAZZ PHARMACEUTICALS.

These have led to 5 R&D programs against serious or debilitating diseases:
cancer, steroid-resistant acute Graft-versus-Host Disease and vascular tumors of the eye.




Upcoming Events

J.P. Morgan 36th Annual Healthcare Conference

Dr Christine Guillen, CEO, will attend the J.P. Morgan 36th Annual Healthcare Conference.

To schedule a meeting, please contact us

Date: 08 January 2018 to 11 January 2018
Location: San Francisco, CA, USA

Jobs

ElsaLys Biotech is always searching for dedicated and motivated employees and we also offers opportunities for student training periods.

 If you would like to join our team, please contact us

CONTACT

Headquarters, R&D, Shipping Address

ELSALYS BIOTECH SAS,
Chez ACCINOV, 317 avenue Jean Jaurès
69007 Lyon
France
☏ +33 (0)4 37 28 73 00

  Google Map

Administrative and Financial Department

ELSALYS BIOTECH SAS, Pépinière de Hautepierre
8 avenue Dante, CS 70033
F-67087 Strasbourg Cedex
France
☏ +33 (0)3 88 29 03 00


To stay in touch with information on ElsaLys Biotech or be contacted by our team, please fill the form below:

 
Fields marked with an asterisk (*) are required!